EU/3/13/1102
Table of contents
About
On 8 February 2013, orphan designation (EU/3/13/1102) was granted by the European Commission to Apeptico Forschung und Entwicklung GmbH, Austria, for Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys for the treatment of high-altitude pulmonary oedema.
Key facts
Active substance |
Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys
|
Disease / condition |
Treatment of high-altitude pulmonary oedema
|
Date of first decision |
08/02/2013
|
Outcome |
Positive
|
EU designation number |
EU/3/13/1102
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
MariahilferStraße 136, Top 1.15
1150 Vienna
Austria
Tel. +43 664 1432 919
Fax +43 125 3303 37795
E-mail: b.fischer@apeptico.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.